Related Experiment Video
Updated: Dec 14, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.6K
Changing the Goal Posts: Prostate-specific Membrane Antigen Targeted Theranostics in Prostate Cancer
1Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, Australia; University of New South Wales, Sydney, Australia.
Seminars in Oncology Nursing
|July 18, 2020
Summary
Prostate-specific membrane antigen (PSMA) theranostics offers precise diagnosis and therapy for prostate cancer. Further research is needed to optimize its clinical application for improved patient outcomes.
Area of Science:
- Oncology
- Nuclear Medicine
- Precision Medicine
Background:
- Prostate-specific membrane antigen (PSMA) is a transmembrane protein significantly over-expressed in prostate cancers.
- PSMA theranostics utilizes small molecule proteins labeled with radionuclides for diagnosis or therapy.
- This approach aligns with precision medicine principles for targeted cancer treatment.
Purpose of the Study:
- To review the significance of PSMA in prostate cancer.
- To evaluate PSMA's role in diagnostic imaging.
- To assess PSMA's potential as a therapy for advanced prostate cancer.
Main Methods:
- A comprehensive literature search was conducted using electronic databases (MEDLINE, Scopus) and professional websites.
Main Results:
- PSMA-directed theranostics demonstrates utility as a sensitive diagnostic tool.
- It can be combined with effective and low-toxicity therapeutic options.
- PSMA theranostics is increasingly integrated into routine prostate cancer care.
Conclusions:
- PSMA theranostics is expanding its role in prostate cancer management.
- Understanding its strengths and limitations is crucial for optimal patient care.
- Ongoing research is necessary to refine its clinical application.
